Sci Rep:白介素-7能够导致前列腺癌细胞的浸润

2019-05-20 AlexYang MedSci原创

白介素-7(IL-7)调控的肿瘤浸润潜在精细机制仍旧不清楚。最近,有研究人员调查了IL-7在肿瘤浸润中的作用,研究人员使用的是转移性前列腺癌PC-3衍生细胞系。研究人员还利用一种Janus激酶(JAK)抑制剂和IL-7阻断抗体评估了IL-7作为一种临床靶标的可能性。研究发现,IL-7能够刺激PC-3细胞创伤愈合迁移和入侵,增加信号转导子和转录激活子5、Akt和细胞外信号调控激酶的磷酸化。另外,JA

白介素-7(IL-7)调控的肿瘤浸润潜在精细机制仍旧不清楚。最近,有研究人员调查了IL-7在肿瘤浸润中的作用,研究人员使用的是转移性前列腺癌PC-3衍生细胞系。研究人员还利用一种Janus激酶(JAK)抑制剂和IL-7阻断抗体评估了IL-7作为一种临床靶标的可能性。

研究发现,IL-7能够刺激PC-3细胞创伤愈合迁移和入侵,增加信号转导子和转录激活子5、Akt和细胞外信号调控激酶的磷酸化。另外,JAK抑制剂和IL-7阻断抗体能够减少PC-3细胞的侵入。IL-7能够促进肿瘤实体的形成和上皮-间质转化(EMT)标记的表达。重要的是,在试验性小鼠转移模型中,与对照比较IL-7Rα慢病毒给药处理PC-3细胞能够显著的增加骨转移。癌症基因组图谱数据库的人类前列腺癌细胞基因表达情况阐释了EMT途径与前列腺癌强烈相关,并高表达IL-7和IL-7Rα。

最后,研究人员指出,他们的数据表明了IL-7和/或IL-7Rα是抑制肿瘤转移的很有希望的靶标。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1252605, encodeId=a4f21252605dc, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Wed May 22 04:48:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372125, encodeId=1c7a13e212511, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Wed May 22 04:48:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620252, encodeId=183e162025229, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Wed May 22 04:48:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040459, encodeId=87dd104045953, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon May 20 16:48:00 CST 2019, time=2019-05-20, status=1, ipAttribution=)]
    2019-05-22 yxch36
  2. [GetPortalCommentsPageByObjectIdResponse(id=1252605, encodeId=a4f21252605dc, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Wed May 22 04:48:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372125, encodeId=1c7a13e212511, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Wed May 22 04:48:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620252, encodeId=183e162025229, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Wed May 22 04:48:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040459, encodeId=87dd104045953, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon May 20 16:48:00 CST 2019, time=2019-05-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1252605, encodeId=a4f21252605dc, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Wed May 22 04:48:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372125, encodeId=1c7a13e212511, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Wed May 22 04:48:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620252, encodeId=183e162025229, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Wed May 22 04:48:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040459, encodeId=87dd104045953, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon May 20 16:48:00 CST 2019, time=2019-05-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1252605, encodeId=a4f21252605dc, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Wed May 22 04:48:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372125, encodeId=1c7a13e212511, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Wed May 22 04:48:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620252, encodeId=183e162025229, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Wed May 22 04:48:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040459, encodeId=87dd104045953, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon May 20 16:48:00 CST 2019, time=2019-05-20, status=1, ipAttribution=)]
    2019-05-20 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Oncogene:雄激素受体调控的microRNAs在治疗抗性和治疗靶标中的研究

雄激素受体(AR)信号是前列腺癌(PC)的主要驱动因子,在晚期抵抗性前列腺癌(CRPC)中也是如此。最近,有研究人员了在致死性疾病中系统性的鉴定microRNAs(miRs)调控的AR活性,他们将表达一个荧光素酶的AR受体的激素响应和激素抵抗PC细胞转染miR抑制剂文库。研究发现,78个抑制剂能够显著的改变AR活性。根据鉴定结果,miR-346、miR-361-3p和miR-197抑制子能够显著的

Mol Cancer Ther:Notch1活性缺失能够抑制前列腺癌的生长和转移

前列腺癌在男性相关死亡原因中仍旧占据主导地位。患有恶性疾病的患者基本都要经历激素阻断治疗。虽然起始的治疗非常有效,这些男性通常在未来2-3年会发展至致死的、去势抵抗性前列腺癌。去势抵抗性前列腺癌的标准治疗方法包括第二代抗雄激素治疗,但是只能延长患者寿命几个月。因此,加深对抵抗性产生机理的理解是必要的,最终目的就是要开发出恶性前列腺癌的新疗法。最近,有研究人员鉴定了Notch1作为前列腺癌的治疗靶标

Prostate:前列腺癌中胞外囊泡来源蛋白组织差异表达分析

前列腺癌(PCa)和正常前列腺细胞系中的胞外囊泡(EVs)蛋白组分析能够促使人们发现PCa新的候选标记。这些蛋白包括了核输出蛋白XPO1(也称为CRM1)、EV相关的PDCD6IP蛋白(也称为ALIX)以及脂肪酸合成酶FASN。最近,有研究人员在详细鉴定过的前列腺癌群体中利用质谱分析和组织芯片(TMA)免疫组化技术调查了XPO1和PDCD6IP表达的差异,从而确定它们的诊断和预后值。研究包括了67

英国NHS倡导,使用水凝胶降低放射治疗前列腺癌患者的副作用

前列腺癌是男性中最常见的癌症,每年在英格兰新诊断出的病例超过40000例。当足够早地发现前列腺癌时,放射治疗是一种非常有效的治疗方法,高能X射线靶向前列腺,杀死癌细胞并阻止扩散。然而附近的健康器官也会受到影响。SpaceOAR水凝胶充当间隔物,通过临时将其远离治疗中使用的高剂量辐射,减少治疗期间损伤直肠的辐射量。水凝胶作为NHS特定创新计划的一部分得到资助,该计划在过去三年中已经使超过300000

Sci Rep:一个很有前景的前列腺癌预测工具PI-RADS V2介绍

最近,有研究人员开发了一个新的工具来改善对前列腺癌(PCa)预测的表现,并减少不必要的活检。研究人员对明确的进行了前列腺活检的患者的临床数据进行了回顾性的分析。PCa相关的风险,包括年龄、前列腺特异性抗原(PSA)、PSA密度(PSAD)、自由PSA(fPSA)、fPSA与PSA比例(%fPSA)、前列腺体积(PV)、直肠指检(DRE)和多参数核磁共振成像(MP-MRI)用于单变量和多变量分析。满

Prostate:CD4+ T浸润能够减弱前列腺癌的化疗敏感性

多烯紫杉醇(Doc)化疗在部分前列腺癌(PCa)案例的治疗中是有效的。然而,大多数患者最后都发展为多烯紫杉醇抗性。肿瘤免疫微环境和分泌的细胞因子在化疗抗性的形成过程中具有重要的作用。之前的研究阐释了CD4+ T细胞在前列腺肿瘤微环境中能够促进PCa恶化;同时,研究人员发现CD4+ T细胞浸润在Doc治疗后的肿瘤中增加。然而,它们对PCa化疗敏感性的影响仍旧未知。最进,有研究人员探索了CD4+ T细